WO2001079195A9 - Nouveaux inhibiteurs de thrombine de type non covalent - Google Patents

Nouveaux inhibiteurs de thrombine de type non covalent

Info

Publication number
WO2001079195A9
WO2001079195A9 PCT/US2001/012276 US0112276W WO0179195A9 WO 2001079195 A9 WO2001079195 A9 WO 2001079195A9 US 0112276 W US0112276 W US 0112276W WO 0179195 A9 WO0179195 A9 WO 0179195A9
Authority
WO
WIPO (PCT)
Prior art keywords
compound according
carbon atoms
substituted
alkyl
hydrogen
Prior art date
Application number
PCT/US2001/012276
Other languages
English (en)
Other versions
WO2001079195A2 (fr
WO2001079195A3 (fr
Inventor
Joseph Edward Semple
Jingjong Jean Cui
Jonathan Zhangi Ho
Odile Esther Levy
Gian Luca Araldi
John Eugene Reiner
Daniel Vanna Siev
Original Assignee
Corvas Int Inc
Joseph Edward Semple
Jingjong Jean Cui
Jonathan Zhangi Ho
Odile Esther Levy
Gian Luca Araldi
John Eugene Reiner
Daniel Vanna Siev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corvas Int Inc, Joseph Edward Semple, Jingjong Jean Cui, Jonathan Zhangi Ho, Odile Esther Levy, Gian Luca Araldi, John Eugene Reiner, Daniel Vanna Siev filed Critical Corvas Int Inc
Priority to AU2001255399A priority Critical patent/AU2001255399A1/en
Publication of WO2001079195A2 publication Critical patent/WO2001079195A2/fr
Publication of WO2001079195A3 publication Critical patent/WO2001079195A3/fr
Publication of WO2001079195A9 publication Critical patent/WO2001079195A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to compounds which are potent inhibitors of thrombin.
  • the present invention relates to novel peptide analogs, their pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof, which are useful as potent inhibitors of blood coagulation in vi tro and in vivo in mammals.
  • the invention relates to methods of using these inhibitors as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.
  • the present invention relates to methods of using these inhibitors as in vi tro diagnostic agents .
  • BACKGROUND AND INTRODUCTION TO THE INVENTION Normal hemostasis is the result of a complex balance between the processes of clot formation (blood coagulation) and clot dissolution (fibrinolysis) .
  • the complex interactions between blood cells, specific plasma proteins and the vascular surface maintain the fluidity of blood unless injury occurs. Damage to the endothelial barrier lining the vascular wall exposes underlying tissue to these blood components. This in turn triggers a series of biochemical reactions altering the hemostatic balance in favor of blood coagulation which can either result in the desired formation of a hemostatic plug stemming the loss of blood or the undesirable formation of an occlusive intravascular thrombus resulting in reduced or complete lack of blood flow to the affected organ.
  • the blood coagulation response is the culmination of a series of amplified reactions in which several specific zymogens of serine proteases in plasma are activated by limited proteolysis. Nemerson, Y. and Nossel, H.L., Ann. Rev. Med., 33: 479 (1982). This series of reactions results in the formation of an insoluble fibrin matrix composed of fibrin and cellular components which is required for the stabilization of the primary hemostatic plug or thrombus. The initiation and propagation of the proteolytic activation reactions occurs through a series of amplified pathways which are localized to membranous surfaces at the site of vascular injury (Mann, K.G. , Nesheim, M.E., Church, .R., Haley, P.
  • This step occurs following the assembly of the prothrombinase complex which is composed of factor Xa, the non-enzymatic co-factor Va, and the substrate prothrombin assembled on the surface of adhered, activated platelets or systemically circulating membranous microparticles.
  • Proteolytic activation of zymogen factor X to its catalytically active form, factor Xa can occur by either the intrinsic or extrinsic coagulation pathways.
  • the intrinsic pathway is referred to as "intrinsic” because everything needed for clotting is in the blood. Saito, H., "Normal Hemostatic Mechanisms", Disorders of Hemostasis , pp. 27-29, Grune & Stratton, Inc. (O.D. Ratnoff, M.D. and CD. Forbes, M.D. edit. 1984).
  • This pathway is comprised of the zymogen serine proteases, factors IX and XI, and the non-enzymatic co-factor, factor VIII.
  • Factor XIa catalyzes the activation of factor IX to factor IXa which in combination with the activated form of factor VIII on an appropriate phospholipid surface, results in the formation of the tenase complex. This complex also catalyzes the formation of the serine protease, factor Xa, from its zymogen, factor X which subsequently results in clot formation.
  • the extrinsic pathway is referred to as "extrinsic" because the tissue factor which binds to and facilitates the activation of factor VII comes from outside the blood. Saito, id .
  • the major components of this pathway are the zymogen serine protease, factor VII, and the membrane bound protein, tissue factor.
  • the latter serves as the requisite non-enzymatic co-factor for this enzyme.
  • the initiation of this pathway is thought to be an autocatalytic event resulting from the activation of zymogen factor VII by trace levels of activated factor VII (factor Vila) , both of which are bound to newly exposed tissue factor on membrane surfaces at sites of vascular damage.
  • factor Vila/tissue factor complex directly catalyzes the formation of the serine protease, factor Xa, from its zymogen, factor X. Exposure of blood to injured tissue initiates blood clotting by the extrinsic pathway.
  • thrombin The formation of thrombin is catalyzed by factor Xa following the assembly of the catalytic prothrombinase complex as reviewed by Mann, K.G. et al . ,
  • thrombin sequestration of factor Xa in the prothrombinase complex also renders it resistant to inhibition by exogenous heparin therapy which also requires antithrombin III to elicit its anticoagulant effect.
  • Thrombin is the primary mediator of thrombus formation. Thrombin acts directly to cause formation of insoluble fibrin from circulating fibrinogen.
  • thrombin activates the zymogen factor XIII to the active transglutaminase factor Xllla which acts to covalently stabilize the growing thrombus by crosslinking the fibrin strands. Lorand, L. and
  • thrombin is the most potent agonist of platelet activation, and it has been demonstrated to be the primary pathophysiologic-mediator of platelet-dependent arterial thrombus formation. Edit, J.F. et al . , J. Clin . Invest . , 84:18 (1989).
  • Thrombin-mediated platelet activation leads to ligand-induced inter-platelet aggregation principally due to the bivalent interactions between adhesive ligands such as fibrinogen and fibronectin with platelet integrin receptors such as glycoprotein Ilb/IIIa which assume their active conformation following thrombin activation. Berndt, M.C. and Phillips, D.R., Platelets in Biology and Pathology, pp.
  • Thrombin-activated platelets can also support further thrombin production through the assembly of new prothrombinase and tenase (factor IXa, factor Villa and factor X) catalytic complexes on the membrane surface of intact activated platelets and platelet-derived microparticles, following thrombin-mediated activation of the non-enzymatic cofactors V and VIII, respectively. Tans, G. et al . , Blood, 77:2641 (1991). This positive feedback process results in the local generation of large concentrations of thrombin within the vicinity of the thrombus which supports further thrombus growth and extension.
  • thrombin has been shown to influence other aspects of hemostasis. These include its effect as an important physiological anticoagulant.
  • the anticoagulant effect of thrombin is expressed following binding of thrombin to the endothelial cell membrane glycoprotein, thrombomodulin. This is thought to result in an alteration of the substrate specificity of thrombin thereby allowing it to recognize and proteolytically activate circulating protein C to give activated protein C (aPC) .
  • aPC activated protein C
  • aPC is a serine protease which selectively inactivates the non-enzymatic co-factors Va and Villa resulting in a down-regulation of thrombin formation by the prothrombinase and tenase catalytic complexes, respectively.
  • Esmon, C.T. Science, 235 : 1348 (1987).
  • the activation of protein C by thrombin in the absence of thrombomodulin is poor.
  • Thrombin has also been shown to be a potent direct mitogen for a number of cell types, including cells of mesenchymal, origin such as vascular smooth muscle cells. Chen, L.B. and Buchanan, J.M., Proc. Natl . Acad . Sci .
  • thrombin acts as a direct secretagogue inducing the release of a number of bioactive substances from vascular endothelial cells including tissue plasminogen activator. Levin, E.G. et al . , Thromb . Haemost . , 5_6:115 (1986).
  • the enzyme can indirectly elaborate potent mitogenic activity on vascular smooth muscle cells by the release of several potent growth factors (e.g., platelet-derived growth factor and epidermal growth factor) from platelet a-granules following thrombin- induced activation. Ross, R., N. Engl . J. Med . , 314:408 (1986).
  • potent growth factors e.g., platelet-derived growth factor and epidermal growth factor
  • abnormal hemostasis With respect to the coronary arterial vasculature, abnormal thrombus formation due to the rupture of an established atherosclerotic plaque is the major cause of acute myocardial infarction and unstable angina. Moreover, treatment of an occlusive coronary thrombus by either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA) is often accompanied by an acute thrombotic reclosure of the affected vessel which requires immediate resolution.
  • PTCA percutaneous transluminal coronary angioplasty
  • venous vasculature With respect to the venous vasculature, a high percentage of patients undergoing major surgery in the lower extremities or the abdominal area suffer from thrombus formation in the venous vasculature which can result in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism.
  • Disseminated intravascular coagulopathy commonly occurs within both vascular systems during septic shock, certain viral infections and cancer and is characterized by the rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the vasculature leading to widespread organ failure.
  • thrombosis in the arterial vasculature is a major clinical concern in today's medicine. It is the leading cause of acute myocardial infarction which is one of the leading causes of death in the western world. Recurrent arterial thrombosis also remains one of the leading causes of failure following enzymatic or mechanical recanalization of occluded coronary vessels using thrombolytic agents or percutaneous transluminal coronary angioplasty (PTCA), respectively.
  • Ross, A.M. Thrombosis in Cardiovascular Disorder, p. 327, W.B. Saunders Co. (Fuster, V. and Verstraete, M. edit. 1991); Califf, R.M. and Willerson, J.T., id .
  • arterial thrombosis is the result of a complex interaction between fibrin formation resulting from the blood coagulation cascade and cellular components, particularly platelets, which make up a large percentage of arterial thrombi.
  • Heparin the most widely used clinical anticoagulant administered i.v., has not been shown to be universally effective in the treatment or prevention of acute arterial thrombosis or rethrombosis . Prins, M.H. and Hirsh, J. , J. Am . Coll . Cardiol . , 67 : 3A (1991) .
  • the need for safe and effective therapeutic anticoagulants has in one aspect focused on the role of the serine protease thrombin in blood coagulation.
  • thrombin cleavage site on the Aa chain of fibrinogen which is the primary physiological substrate for thrombin, is reported to contain a glycine residue in this position while the cleavage site on the Bb chain contains a serine, as shown below: P4 P3 P2 PI PI'
  • substrate-like peptidyl derivatives such as D-phenylalanyl-prolyl-argininal (D-Phe-Pro-Arg-al) , D-phenylalanyl-prolyl-arginine-chloromethyl ketone (P-PACK) and acetyl -D-phenylalanyl-prolyl-boroarginine (Ac- (D-Phe) -Pro-boroArg) have been reported to inhibit thrombin by directly binding to the active site of the enzyme.
  • P-PACK D-phenylalanyl-prolyl-argininal
  • P-PACK D-phenylalanyl-prolyl-arginine-chloromethyl ketone
  • Ac- (D-Phe) -Pro-boroArg acetyl -D-phenylalanyl-prolyl-boroarginine
  • Peptidyl compounds which are said to be active site inhibitors of thrombin but which differ in structure from those containing an uncharged amino acid in the P3 recognition subsite have been reported.
  • Argatroban also called 2R, 4R-4 -methyl -1- [N-2- (3-methyl-l, 2, 3 , 4-tetrahydro-8-qui nolinesulfonyl) -L-argininyl] -2-piperdinecarboxylic acid
  • Argatroban also called 2R, 4R-4 -methyl -1- [N-2- (3-methyl-l, 2, 3 , 4-tetrahydro-8-qui nolinesulfonyl) -L-argininyl] -2-piperdinecarboxylic acid
  • Argatroban has been reported to be a potent antithrombotic agent in several experimental models of acute arterial thrombosis. Jang, I.K. et al . , in both Circulation, 8JL:219 (1990) and Circ . Res . , 67:1552 (1990) .
  • Hirudin and certain peptidyl derivatives of hirudin have been reported to inhibit both conversion of fibrinogen to fibrin and platelet activation by binding to either both the active site and exo site, or the exo site only, of thrombin. Markwardt, F., Thromb . Haemostas . , 66:141 (1991). Hirudin is reported to be a 65 amino acid polypeptide originally isolated from leech salivary gland extracts. It is said to be one of the most potent inhibitors of thrombin known. Marki , W.E.
  • Hirugen has been reported to be a peptide derived from the anionic carboxy-terminus of hirudin. It is reported to bind only to the anion binding exo-site of thrombin and thereby inhibit the formation of fibrin but not the catalytic turnover of small synthetic substrates which have access to the unblocked active site of the enzyme. Maraganore, J.M. et al . , J " . Biol . Chem . ,
  • hirugen has also been reported to enhance the catalytic turnover of certain small synthetic substrates by thrombin, indicating that a conformational change in the enzyme active site may accompany occupancy of the exo-site. Liu, U.W. et al . , J “ . Biol . Chem . , 266:16977 (1991). Hirugen also is reported to block thrombin-mediated platelet aggregation. Jakubowski , J.A. and Maraganore, J.M., Blood, 7_5:399 (1990).
  • a group of synthetic chimeric molecules comprised of a hirugen-like sequence linked by a glycine-spacer region to the peptide, D-phenylalanyl-prolyl -arginine, which is based on a preferred substrate recognition site for thrombin, has been termed to be hirulog.
  • Maraganore et al . U.S. Patent No. 5,196,404 (March 23, 1993).
  • the hirugen-like sequence is said to be linked to this peptide through the C-terminal end of the peptide.
  • the hirulogs have been reported to be an effective antithrombotic agents in preventing both fibrin-rich and platelet-rich thrombosis. Maraganone, J.M. et al . , Thromb . Haemostas . , 65:651 at abstract 17 (1991). Certain benzamidines have been reported to inhibit thrombin though non-selectively . 4-amidinophenylpyruvic acid (APPA) has been reported to be a thrombin inhibitor with low toxicity and favourable pharmacokinetics . However, this compound was reported to be non-selective, inhibiting trypsin, plasmin and kallikrein. Markwardt et al . , Thromb .
  • Benzamidine-derived structures which have been reported to inhibit thrombin include the cyclic amides of N ⁇ -substituted 4-amidinophenylalanine and 2-amino-5- (4-amidinophenyl) -1-valeric acid.
  • the inhibitory constant displayed by these compounds was reported to be in the micromolar range. Markwardt et al . , Thromb . Res . , 1/7:425-31 (1980).
  • the present invention is directed to compounds having a pyridinone or pyrazinone group at P3 and at PI either a cyclic amino or amidino derivative or a bicyclic group. These compounds have activity as inhibitors of thrombin.
  • the present invention is directed to compounds of formula (I) : wherein
  • R 1 is selected from hydrogen, alkyl of 1 to about 4 carbon atoms, aryl of about 6 to about 14 carbon atoms and aralkyl of about 6 to about 16 carbon atoms;
  • (B) Ri is selected from the group consisting of: (1) alkyl of 1 to about 12 carbon atoms which is optionally substituted with Y x and/or Y 2 ,
  • heterocycloalkyl of 4 to about 10 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from the group consisting of oxygen, nitrogen, and S(0) ⁇ , wherein i is 0, 1 or 2, which is optionally mono-, di-, or tri-substituted on the ring with Y 1# Y 2 and/or Y 3 ,
  • — N G — N G including — / , wherem - is a 5 to 7 member heterocycle of 3 to 6 ring carbon atoms, where G is -CH 2 -, -O- , -S( 0)-, -S(0) 2 - or -S-, which is optionally mono-, di-, or tri-substituted on the ring carbons with Y 1# Y 2 and/or Y 3 ,
  • alkenyl of about 2 to about 6 carbon atoms which is optionally substituted with cycloalkyl of about 3 to about 8 carbon atoms, which is optionally mono-, di-, or tri-substituted on the ring carbons with Y 1( Y 2 and/or Y 3 ,
  • aryl of about 6 to about 14 carbon atoms which is optionally mono-, di- or tri-substituted
  • heteroaryl of about 5 to about 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally mono-, di-, or tri-substituted with Yi, Y 2 , and/or Y 3 ,
  • aralkyl of about 7 to about 15 carbon atoms which is optionally substituted on the alkyl chain with hydroxy or halogen and mono-, di-, or tri-substituted in the aryl ring with Y lf Y 2 , and/or Y 3 ,
  • heteroaralkyl of 5 to 14 ring' atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally substituted on the alkyl chain with hydroxy or halogen and optionally mono-, di- or tri-substituted on the ring with Yi, Y 2 , and/or Y 3 ,
  • heteroaralkenyl of 5 to 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally mono-, di- or tri-substituted on the ring with Y 1# Y 2 , and/or Y 3 ,
  • each Y 1( Y 2 , and Y 3 is independently selected from the group consisting of halogen, cyano, nitro, tetrazolyl optionally substituted with alkyl of 1 to about 6 carbon atoms, guanidino, amidino, methylamino, methylguanidino, -CF 3 , -CF 2 CF 3 , -CH(CF 3 ) 2 , -C(OH) (CF 3 ) 2 , -OCF 3 , -OCF 2 CF 3 , -OCF 2 H,
  • Yi and Y 2 are selected together to be -0[C(Z 3 ) (Z 4 )] r 0- or -0[C(Z 3 ) (Z 4 )] r+ ⁇ -, wherein r is an integer from 1 to 4 and Z 3 and Z 4 are independently selected from the group consisting of hydrogen, alkyl or 1 to about 12 carbon atoms, aryl of about 6 to about 14 carbon atoms, heteroaryl of about 5 to about 14 ring atoms having 1 to about 9 carbon atoms, aralkyl of about 7 to about 15 carbon atoms, and heteroaralkyl of about 5 to about 14 ring atoms; (C) D is
  • R 2 is selected from hydrogen, halogen and alkyl of 1 to about 6 carbon atoms ;
  • R 3 is selected from hydrogen, alkyl of 1 to about 6 carbon atoms, cycloalkyl of 3 to about 7 carbon atoms, alkoxy of 1 to about 5 carbon atoms and trifluoromethyl ;
  • R 4 is hydrogen, alkyl of 1 to about 8 carbon atoms, hydroxy, alkoxy of 1 to about 8 carbon atoms, aralkyl of about 7 to about 15 carbon atoms, alkyl of 1 to about 5 carbon atoms substituted with cycloalkyl of 3 to about 8 carbon atoms, -NHR 5 , -S(0) t R5, and C(0)0R 5 ;
  • t 0, 1 or 2;
  • R 5 is hydrogen; alkyl of 1 to about 4 carbon atoms, aryl of about 6 to about 14 carbon atoms which is optionally mono-, di- or tri-substituted with Yi Y 2( and/or Y 3 ; heteroaryl of about 5 to about 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally mono-, di-, or tri-substituted with Y lf Y 2 , and/or Y 3 ; aralkyl of about 7 to about 15 carbon atoms which is optionally substituted on the alkyl chain with hydroxy or halogen and mono-, di-, or tri-substituted in the aryl ring with Yi, Y 2 , and/or Y 3 ; heteroaralkyl of 5 to 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are
  • R 6 is hydrogen or alkyl of 1 to about 3 carbon atoms
  • R 6a and R 6 are independently selected from hydrogen, fluoro, chloro and alkyl of 1 to about 3 carbon atoms
  • R-7a is alkyl of 1 to about 6 carbon atoms, alkoxy of 1 to about 6 carbon atoms, amino, alkylamino of 1 to about 6 carbon atoms or dialkylamino of 2 to about 12 carbon atoms
  • R 7b is hydrogen, acyl, or alkyl of 1 to about 6 carbon atoms
  • Q 7 , Q 8 and Q 9 are independently selected from C(R 6a )/ N, S and 0, provided that (i) Q 7 , Q 8 and Q 9 are not all C(R 6a ) and (ii) only one of Q 7 , Q 8 and Q 9 can
  • R 8 and R 9 are independently selected from hydrogen, hydroxy, alkyl of 1 to about 4 carbon atoms, alkyl of 1 to about 4 carbon atoms substituted with alkoxy of 1 to about 4 carbon atoms, alkoxy of 1 to about 6 carbon atoms, halogen and trifluoromethyl;
  • R ⁇ is hydrogen or alkyl of 1 to about 3 carbon atoms;
  • R 13 is hydrogen or alkyl of 1 to about 3 carbon atoms;
  • R i2 and R 13 taken together form
  • Qi is C(R ⁇ s), C(R i6 ) (Ri ⁇ a), N, N(R 15a ), or a direct link;
  • Q 2 is C(Ri 5 ), C(R 17 ) (Ri7a), N, N(R 15 ),
  • Q 3 is C(R ⁇ s), C(R ⁇ ) (Ri ⁇ a) , N or N(R ⁇ sa) ;
  • Q 4 is C(R ⁇ 5 ), C(R ⁇ s) (Risa) , N, N(R ⁇ 5a ),
  • Q 5 is C(R 20 ), C(R 0 ) (R 2 oa) or N;
  • R 15 is NR 22 R 23 or -0R 22 ;
  • R ⁇ 5a is hydrogen, alkyl of 1 to about 3 carbon atoms, NR 22a R 23a or -0R 22a ;
  • Ri6 Ri7/ Ri8 Ri9/ R 2 0 and R 2 ⁇ are independently selected from hydrogen, alkyl of 1 to about 3 carbon atoms substituted with alkoxy of 1 to about 3 carbon atoms, alkoxy of 1 to about 4 carbon atoms; halogen and trifluoromethyl;
  • Ri6a/ Ri7a/ Ri ⁇ a Ri9a/ R 2 o a and R 2 ia are independently hydrogen or absent;
  • R 23 and R 23a are independently hydrogen or alkyl of 1 to about 3 carbon atoms ;
  • R 24 is alkyl of 1 to about 6 carbon atoms or alkoxy of 1 to about 6 carbon atoms; with the provisos that:
  • Q 2 , Q 3 and Q 4 can be C(R ⁇ 5 ) or N(R ⁇ 5a ) ;
  • Qi, Q 2 , Q 3 and Q 4 are not all heteroatoms; and with the further provisos that (a) when J is
  • the present invention is directed to compounds which are potent inhibitors of thrombin. According to a preferred aspect, these compounds comprise novel serine protease inhibitors.
  • the present invention is also directed to pharmaceutical compositions which comprise one of these compounds and a pharmaceutically acceptable carrier. These compounds and pharmaceutical compositions are potent inhibitors of blood coagulation in vi tro and in vivo in mammals.
  • These compounds and pharmaceutical compositions may be used as therapeutic agents for treating disease states in mammals which are characterized by abnormal thrombosis.
  • a further aspect of the present invention is directed to the use of these compounds and pharmaceutical compositions for treatment of disease states in mammals characterized by abnormal thrombosis.
  • An alternate aspect of the present invention is directed to methods of using these thrombin inhibitors as in vitro diagnostic agents.
  • the present invention is directed to methods of using the compounds and pharmaceutical compositions of the present invention for the prevention of thrombosis in a mammal suspected of having a condition characterized by abnormal thrombosis, comprising administering to said mammal a therapeutically effective amount of a compound of the present invention or pharmaceutical composition comprising such a compound.
  • R 1# X, D, J and E are as defined in connection with formula (I) .
  • alkenyl refers to unsaturated aliphatic groups having at least one double bond.
  • alkynyl refers to unsaturated aliphatic groups having at least one triple bond. r
  • alkyl refers to saturated aliphatic groups including straight-chain, branched-chain and cyclic groups.
  • alkoxy and alkoxy1 refer to a group having the formula, R-0-, wherein R is an alkyl group.
  • Q alkoxycarbonyl refers to -C(0)OR wherein R is alkyl.
  • aminoalkyl refers to an alkyl group substituted with an amino (NH 2 ) group.
  • alkenyl refers to an alkenyl group 5 substituted with an aryl group.
  • alkenyl group has from 2 to about 6 carbon atoms.
  • aralkyl refers to an alkyl group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, all of which may 0 be optionally substituted. Preferably the alkyl group has from 1 to about 5 carbon atoms .
  • aryl refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes a carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.
  • aryloxy refers to a group having the formula, R-0-, wherein R is an aryl group.
  • aralkoxy refers to a group having the formula, R-0-, wherein R is an aralkyl group.
  • amino acid refers to both natural and unnatural amino acids in their D and L stereoisomers, if their structures allow such stereoisomeric forms, and their analogs.
  • Natural amino acids include alanine (Ala) , arginine (Arg) , asparagine (Asn) , aspartic acid (Asp) , cysteine (Cys) , glutamine (Gin) , glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (lie), leucine (Leu) , lysine (Lys) , methionine (Met) , phenylalanine (Phe) , proline (Pro) , serine (Ser) , threonine (Thr) , tryptophan (Trp) , tyrosine (Tyr) and valine (Val) .
  • Unnatural amino acids include, but are not limited to, azetidinecarboxylic acid, 2-aminoadipic acid, 3-aminoadipic acid, beta-alanine, aminopropionic acid, 2-aminobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-aminoisobutyric acid, 2-aminopimelic acid, 2,4 diaminoisobutyric acid, demosine, 2 , 2 ' -diaminopimelic acid, 2 , 3-diaminopropionic acid, N-ethylglycine, N-ethylasparagine, hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hydroxyproline, isodesmosine, allo- isoleucine, N-methylglycine, N-methylisoleucine, N-methylvaline, norvaline, norleucine
  • Amino acid analogs include the natural and unnatural amino acids which are chemically blocked, reversibly or irreversibly, or modified on their N-terminal amino group or their side-chain groups, as for example, methionine sulfoxide, methionine sulfone, S- (carboxymethyl) -cysteine, S- (carboxymethyl) -cysteine sulfoxide and S- (carboxymethyl) -cysteine sulfone.
  • amino acid residue refers to radicals having the structure: (1) -C(0)-R-NH-, wherein R typically is -CH(R')-# wherein R' is H or a carbon
  • N containing substituent or (2) ' , wherein p is 1, 2 or 3 representing the azetidinecarboxylic acid, proline or pipecolic acid residues, respectively.
  • amino acid analog refers to an amino acid wherein either the C-terminal carboxy group, the N-terminal amino group or side-chain functional group has been chemically modified to another functional group.
  • aspartic acid- (beta-methyl ester) is an amino acid analog of aspartic acid
  • N-ethylglycine is an amino acid analog of glycerine
  • alanine carboxamide is an amino acid analog of alanine.
  • Arginine mimic side chain or “side chain of an arginine mimic” refers to a group of atoms which spatially and electronically resemble or mimic the normal arginine side chain. These groups include the cyclic R 5 groups defined in connection with formula (I).
  • aryl refers to phenyl substituted by carbocyclic or heterocyclic aryl as defined herein, ortho, meta or para to the point of attachment of the phenyl ring.
  • Carbocyclic refers to a group having one or more rings wherein the ring atoms are all carbon atoms and includes groups having aryl, cycloalkyl, and unsaturated cycloalkyl or a combination of such rings. Such groups include cyclohexyl, cycloheptenyl , tetrahydronaphthyl , phenyl, naphthyl, and the like. "Carbocyclic aryl” refers to aromatic groups wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and naphthyl groups, all of which may be optionally substituted.
  • Suitable carbocyclic aryl groups include phenyl and naphthyl.
  • Suitable substituted carbocyclic aryl groups include indene and phenyl substituted by one to two substituents such being advantageously lower alkyl, hydroxy, lower alkoxy, lower alkoxycarbonyl, halogen, trifluoromethyl, nitro, and cyano.
  • Substituted naphthyl refers to 1- or 2 -naphthyl substituted by lower alkyl, lower alkoxy, or halogen.
  • Carboxylate mimic or “carboxylic acid mimic” refers to a group which spatially and electronically mimics a carboxylic acid and provides a net negative charge, i.e., an anion, and also has a pKa value similar to that of a corresponding carboxylic acid, preferably having a pKa of about 4 to 5.
  • Cycloalkenyl or “unsaturated cycloalkyl” refers to a cyclic alkenyl group, that is, a cycloalkyl group modified by having at least one double band. Suitable cycloalkenyl groups include, for example, cyclopentenyl and cyclohexenyl .
  • Cycloalkyl refers to a cyclic alkyl group. Suitable cycloalkyl groups include, for example, cyclohexyl, cyclopropyl, cyclopentyl, and cycloheptyl.
  • Cyclohexylmethyl refers to a cyclohexyl group attached to CH 2 .
  • Fused carbocyclic refers to a group having multiple rings which are fused, including multicyclic fused carbocyclic rings having both aromatic and non-aromatic rings. Suitable fused carbocyclic rings include fluorenyl, tetralin and the like.
  • fused carbocyclic alkyl refers to an alkyl group substituted with a fused carbocyclic ring moiety, preferably a multicyclic fused carbocyclic ring having both aromatic and nonaromatic rings. Suitable fused carbocyclic alkyl groups include fluorenyl methyl and the like.
  • halogen refers to fluorine, chlorine, bromine and iodine .
  • heteroatom as defined herein is an atom other than carbon or hydrogen, e.g., typically, oxygen, nitrogen or sulfur.
  • Heterocyclic refers to a group having 1 or more rings wherein the ring atoms are carbon atoms or heteroatoms, and includes rings that are reduced, saturated, unsaturated and aromatic and, if the group has more than one ring, includes a combination of such rings. Suitable heteroatoms include oxygen, nitrogen and S(0) ⁇ wherein i is 0, 1 or 2.
  • heterocyclic groups include groups having (i) heterocyclo rings (ii) unsaturated heterocyclo rings, (iii) heteroaryl rings or (iv) a combination of such rings.
  • Heteroaryl refers to aromatic groups having a mixture of carbon atoms and heteroatoms.
  • Preferred heteroaryl groups include those having 5 to 14 ring atoms and from 1 to 9 carbon atoms and the remainder of the ring atoms heteroatoms.
  • Heteroaryl groups include those heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems. Suitable heteroatoms include oxygen, nitrogen, and sulfur.
  • Typical heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, pyrimidyl, pyrazinyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl and the like.
  • Heteroaralkenyl refers to an alkenyl group substituted with a heteroaryl group. Preferably the alkenyl group has from 2 to about 6 carbon atoms.
  • Heteroaralkyl refers to an alkyl group substituted with a heteroaryl group. Preferably the alkyl group has from 1 to about 6 carbon atoms.
  • heteroatom as defined herein is an atom other than carbon or hydrogen, e.g., typically oxygen, nitrogen, or sulfur.
  • Heterocyclo refers to a reduced heterocyclic ring system comprised of carbon, nitrogen, oxygen and/or sulfur atoms, and includes such heterocyclic systems described in "Handbook of Chemistry and Physics", 49th edition, 1968, R.C. Weast, editor; The Chemical Rubber Co., Cleveland, OH. See particularly Section C, Rules for Naming Organic Compounds, B. Fundamental Heterocyclic Systems.
  • Unsaturated heterocyclo refers to a heterocyclo group which is modified by having at least one double bond, but which is not aromatic.
  • Heterocycloalkyl refers to an alkyl group substituted with a heterocyclo group.
  • the alkyl group has from 1 to about 6 carbon atoms.
  • hydrocarbyl denotes an organic radical composed of carbon and hydrogen which may be aliphatic (including alkyl, alkenyl and alkynyl groups and groups which have a mixture of saturated and unsaturated bonds), alicyclic (such as cycloalkyl), aromatic (such as aryl) or combinations thereof, and may refer to straight-chained, branched-chain or to cyclic structures or to radicals having a combination thereof, as well as to radicals substituted with halogen atom(s) or heteroatoms, such as nitrogen, oxygen and sulfur and their functional groups (such as amino, alkoxy, aryloxy, lactone groups, and the like), which are commonly found in organic compounds and radicals.
  • hydroxyalkyl refers to an alkyl group substituted with a hydroxy group.
  • lower referred to herein in connection with organic radicals or compounds defines such with up to and including 6, preferably up to and including 4 and advantageously one or two carbon atoms.
  • Such groups may be straight chain or branched chain.
  • Perfluoroalkyl refers to an alkyl group which has every hydrogen replaced with fluorine.
  • Perfluoroaryl refers to an aryl group which has every hydrogen replaced with fluorine.
  • Perfluoroarylalkyl or “Perfluoroaralkyl” refers an aralkyl group in which every hydrogen on the aralkyl moiety is replaced with fluorine.
  • “Pharmaceutically acceptable salt” includes salts of the compounds of the present invention derived from the combination of such compounds and an organic or inorganic acid. In practice the use of the salt form amounts to use of the base form. The compounds of the present invention are useful in both free base and salt form, with both forms being considered as being within the scope of the present invention.
  • quaternary ammonium salt refers to compounds produced by reaction between a basic nitrogen in an R substituent and an alkylhalide, arylhalide, and aralkylhalide .
  • Other reactants with good leaving groups may also be used, such as alkyl trifluoromethanesulfonates, alkyl methanesulfonates, and alkyl p-toluenesulfonates .
  • a quaternary ammonium salt has a positively charged nitrogen in the R substituent.
  • Pharmaceutically acceptable counterions include C1-, Br “ , I " , CF 3 C(0)0 " and CH 3 C(O)0 " . The counterion of choice can be made using ion exchange resin columns.
  • R groups contain basic nitrogens: 3- (R) -quinuclidine, 3- (S) -quinuclidine, 3-yl-2-ethyl-4 (3H) -quinazolinone, ethyl morpholine, ethyl piperidine, 2- (2 -ethyl) pyridine, and 4- (methyl) -5-hydroxy-6-methyl-3- pyridine methanol.
  • Trihydrocarbylsilyl refers to the group
  • each R is an independently selected hydrocarbyl group .
  • terminal carbon refers to the carbon atom of a straight chain alkyl which is furthest from the parent structure.
  • Ac 2 0 refers to acetic anhydride.
  • AIBN refers to 2 , 2 ' -azobisisobutyronitrile .
  • 9-BBN refers to 9-borabicyclo [3.3.1] nonane .
  • Bn refers to benzyl .
  • Boc or “BOC” refers to t-butoxycarbonyl .
  • Boc 2 0 refers to Boc anhydride or di-tert-butyl dicarbonate .
  • BOP refers to benzotriazol-1-yl-oxy-tris- (dimethylamino) -phosphonium hexafluorophosphate .
  • BnS0 2 or “BzlS0 2” refers to benzylsulfonyl .
  • t-BuOK refers to potassium tert-butoxide.
  • Cbz or “CBz” refers to benzyloxycarbonyl.
  • CsOAc refers to Cesium acetate.
  • DCA refers to dichloroacetic acid.
  • DCC refers to N,N' -dicyclohexylcarbodiimide .
  • DCE refers to 1,2-dichloroethane.
  • DCM refers to dichloromethane (also called methylene chloride) .
  • DEAD refers to diethyl azodicarboxylate.
  • DHP refers to 3 , 4 -dihydro-2H-pyran.
  • DF refers to N,N-dimethylformamide .
  • DMSO refers to dimethyl sulfoxide.
  • DMAP refers to 4-dimethylamino-pyridine .
  • DPPA refers to diphenylphosphoryl azide.
  • EAC l-ethyl-3- (3-dimethylamino-propyl) carbodiimide hydrochloride salt .
  • Et 3 N refers to triethylamine.
  • EtOAc refers to ethyl acetate.
  • EtOH refers to ethanol .
  • HATU refers to 0- (7-azabenzotriazol-l-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate .
  • HBTU refers to 2- (lH-benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate .
  • HCl refers to hydrochloric acid.
  • HOAc refers to acetic acid.
  • HOAt refers to l-hydroxy-7-azabenzotriazole .
  • HBt refers to 1-hydroxybenzotriazole monohydrate .
  • HPLC refers to high pressure liquid chromatography.
  • i-BuOCOCl refers to isobutyl chloroformate .
  • KAc refers to potassium acetate.
  • LiAlH 4 refers to lithium aluminum hydride.
  • LiAlH 2 (OEt) refers to lithium diethoxy aluminum hydride.
  • Me refers to methyl .
  • MeOH refers to methanol .
  • NaOH refers to sodium hydroxide.
  • NBS refers to N-bromosuccinimide .
  • NMM refers to N-methylmorpholine.
  • Ph 3 P or “PPh 3 " refers to triphenylphosphine.
  • 2-PrPen refers to 2-propylpentanoyl .
  • pTSA catalyst refers to para-toluenesulfonic acid catalyst.
  • TBTU refers to 2- (lH-benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium tetrafluoroborate .
  • TAA triethylamine
  • THF trifluoroacetic acid
  • THF tetrahydrofuran
  • TLC thin layer chromatography
  • Figure 1 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • “i” through “ix” are defined as follows: i) H 2 balloon, 10% Pd/C, EtOAc, room temperature 48 hours, 51% yield; ii) Ac 2 0/KOAc, CHC1 3 , reflux 2 hours, flash chromatography, 92% yield; iii) isoamylnitrite, KOAc, catalytic amount 18-crown-6, Ac 2 0, CHC1 3 , reflux 28 hours, 95% yield; iv) aqueous 48% HBr, room temperature 46 hours, 84% yield; v) DHP, THF, reflux 2 hours, 72% yield; vi) NaN 3 , DMF, 90°C 0.5 hour, 83% yield; vii) LiAlH 4 , THF, 0°C 1 hour; viii) EDC, HOAt, NMM, DMF
  • Figure 2 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • “i” through “vi” are defined as follows: i) S0 3 -DMF, DCE, reflux 1 hour; ii) SOCl 2 , reflux 1 to 3 hours, 94% yield; iii) 3 -amino-6 -methyl -1- tert -butyl -methylenecarboxy-2 -pyridinone , TEA, acetonitrile, room temperature 16 hours, 64% yield; iv) 4M HCl, dioxane, 0°C, 8 hours, quantitative yield; v) EDC, HOAt, DIEA, DMF, room temperature 16 hours; vi) 4M HCl in dioxane, 60°C 1 hour, 6% yield.
  • Figure 3 depicts reaction schemes for the synthesis of certain compounds having thrombin inhibitory activity.
  • “i” through “ix” are defined as follows: i) CuCN, DMF, reflux 6 hours, 76% yield; ii) NH 2 NH 2 , ethanol, reflux under N 2 17 hours, 91% yield; iii) B 2 H 6 /THF, 0°C to room temperature 15 hours; iv) 6N HCl , water and methanol , room temperature 6 hours neutralize with NaOH; v) Boc 2 0 in THF, methanol, room temperature 15 hours, 60% yield; vi) 2N HCl, methanol, dioxane, room temperature 4 hours; vii) OH " resin; viii) HOAt, EDC, DMF, room temperature 15 hours; and ix) HOAt, EDC, DMF, room temperature 15 hours.
  • Figure 4 depicts reaction schemes for the synthesis of certain compounds having thrombin inhibitory activity.
  • "i” through “x” are defined as follows: i) CuCN, DMF, reflux 5 hours; ii) NBS, AIBN, CC1 4 , reflux 4.5 hours; iii) phthalimide, Cs 2 C0 3 , DMF, room temperature 0.5 hour; iv) hydrazine, n-butanol, reflux 5 minutes; v) Boc 2 0, DCM, room temperature 1 hour; vi) hydrazine, n-butanol, reflux 22 hours; vii) 2M HCl in dioxane, room temperature 0.5 hour; viii) OH " resin; ix) HOAt, EDC, DMF, room temperature 15 hours; and x) HOAt, EDC, DMF, room temperature 15 hours. These procedures are more fully described in Examples 19 to 26.
  • Figure 5 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • “i” through “vii” are defined as follows: i) NaN 3 , DMF, room temperature 15 hours; ii) Ph 3 P, THF/H 2 0, room temperature 15 hours; iii) Boc0 in DMF, room temperature overnight; iv) t-BuOK, DMF, room temperature 30 minutes, add 29, room temperature 15 hours, 70°C, 24 hours; v) 2N HCl, methanol/dioxane, room temperature 0.5 hour; vi) OH " resin; and vii) HOAt, EDC, DMF, room temperature 15 hours. These procedures are more fully described in Examples 27 to 30.
  • Figure 6 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • “i” through “viii” are defined as follows: i) NBS, benzoyl peroxide, CC1 4 , reflux 6 hours; ii) NaN 3 , DMF, room temperature 15 hours; iii) Ph 3 P, THF/H 2 0, 0°C, 0°C to room temperature 15 hours,
  • Figure 7 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • "i” through “viii” are defined as follows: i) NBS, benzoyl peroxide, CC1 4 , reflux 6 hours; ii) NaN 3 , DMF, room temperature 15 hours; iii) Ph 3 P, THF/H 2 0, room temperature 15 hours; iv) DCM, IM Boc 2 0 in THF, room temperature 15 hours; v) hydrazine, n-butanol, reflux 4 hours; vi) 2M HCl methanol/dioxane, room temperature 3 hours; vii) OH " resin; and viii) HOAt, EDC, DMF, room temperature 15 hours.
  • Figure 8 depicts a reaction scheme for the synthesis of a compound of the present invention.
  • "i” through “xx” are defined as follows: i) DPPA, Et 3 N, dioxane, reflux 20 hours; ii) tert-butanol , Et 3 N, reflux 20 hours; iii) Cs 2 C0 3 , DMF, room temperature 15 hours; iv) 9-BBN, THF, 0°C one hour, 5°C, 16 hours; v) warm 60 to room temperature, 3M NaOH, Pd(PPh 3 ) 4 , reflux, 7 hours; vi) 2M HCl/dioxane, 5°C, fifteen hours, room temperature, 4 hours; vii) OH " resin; viii) CH 3 CN, ⁇ -toluene-sulfonyl chloride, 2, 4 , 6-collidine, room temperature 15 minutes; ix) hydroxylamine hydroch
  • Figure 9 depicts a reaction scheme for the synthesis of a compound of the present invention.
  • "i” through “x” are defined as follows: i) 9-BBN, THF, 0°C one hour, 5°C 18 hours, warm to room temperature; ii) compound 61, Pd(PPh 3 ) 4f 2M NaOH, reflux 2 hours, cool to room temperature; iii) 30% H 2 0 2 /H 2 0, room temperature about one hour; iv) ZnEt 2 in hexane/DCM, CH 2 I 2 , 69 (see Example 53) in DCM, 0°C to room temperature 15 hours; v) 2N NaOH, room temperature overnight; vi) Ph 3 P, THF, DEAD, 0°C ten minutes, room temperature 30 minutes; vii) 4M HCl/EtOAc, room temperature 3 hours; viii) CH 3 CN, 2 , 4 , 6-collidine, ⁇ -toluene sulfon
  • Figure 10 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • "i” through “viii” are defined as: i) NBS, AIBN, CC1 4 , reflux 8 hours; ii) NaN 3 , DMF, room temperature 15 hours; iii) Ph 3 P, THF, 0°C, 0°C to room temperature 15 hours; iv) Boc 2 0, DCM, room temperature 2 hours; v) t-BuOK, DMF, room temperature 15 hours; vi) 2N HCl, methanol/dioxane, room temperature 5 hours; vii) OH " resin; and viii) HOAt, EDC, DMF, room temperature 15 hours.
  • Figure 11 depicts a reaction scheme for the synthesis of a compound of the present invention.
  • "i” through “vi” are defined as follows: i) hydroxylamine HCl, Et 3 N, ethanol, room temperature 2 days; ii) methanol (anhydrous), acetylchloride, reflux 2 hours; iii) HOAt, EDC, DMF, room temperature 15 hours; iv) pyridine, reflux 3 hours; v) LiOH-H 2 0 methanol/water, room temperature 10 hours; and vi) HOAt, EDC, NH 4 C1, Et 3 N, DMF, room temperature 15 hours.
  • Figure 12 depicts a reaction scheme for the preparation of a compound having thrombin inhibitory activity.
  • "i” through “iv” are defined as follows: i) hydrazine, n-butanol, reflux 22 hours; ii) 2M HCl in dioxane, room temperature 3 hours; iii) OH " resin; and iv) HOAt, EDC, DMF, room temperature 15 hours.
  • Figure 13 depicts reaction schemes for the synthesis of certain compounds which have a 3- aminoindazole at PI.
  • "i” through “vi” are defined as follows: i) EDC, HOAt, NMM, DMF, room temperature 16 hours; ii) EDC, HOAt, NMM, DMF, room temperature 13 hours; iii) EDC, HOAt, NMM, DMF, room temperature 13 hours; iv) EDC, HOAt, NMM, DMF, room temperature 16 hours; v) EDC, HOAt, NMM, DMF, room temperature 13 hours; and vi) EDC, HOAt, NMM, DMF, room temperature 13 hours.
  • Figure 14 depicts a reaction scheme for the synthesis of an intermediate which may be used in the synthesis of a compound of the present invention having a
  • Figure 15 depicts reaction schemes for the synthesis of certain compounds having an indazole group as PI.
  • "i” through “xiv” are defined as follows: i) EDC, HOAt, NMM, DMF, room temperature 16 hours; ii) 4M HCl, dioxane, 60°C 2 hours; iii) EDC, HOAt, NMM, DMF, room temperature 16 hours; iv) 4M HCl, dioxane, 60°C 2 hours; v) EDC, HOAt, NMM, DMF, room temperature 16 hours; vi) 4M HCl, dioxane, 60 °C 2 hours; vii) EDC, HOAt, NMM, DMF, room temperature 16 hours; viii) 4M HCl, dioxane, 60°C 2 hours; ix) EDC, HOAt, NMM, DMF, room temperature 16 hours; x) 4M
  • Figure 16 depicts a reaction scheme for the synthesis of a compound of the present invention.
  • "i” through “xviii” are defined as follows: i) CsOAc, DMF, room temperature 16 hours; ii) hydroxylamine HCl, Et 3 N, ethanol, room temperature, one week; iii) Cs 2 C0 3 , DMF, room temperature 16 hours; iv) LiOH-H 2 0, methanol, H 2 0, room temperature 48 hours; v) DCM, CBr 4 , Ph 3 P, room temperature 30 minutes; vi) Et 4 NCN, CH 3 CN, room temperature 72 hours; vii) hydroxylamine HCl, Et 3 N, ethanol, room temperature 72 hours; viii) acetone, Et 3 N, -5°C, benzyl chloroformate, 0°C 30 minutes; ix) - 5°C, NaN 3 , H 2 0, 3°C, 1 hour; x) toluene, 65°C, 16
  • Figure 17 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • "i” through “v” are defined as follows: i) Cu(I)CN, DMF, reflux, 20 hours; ii) DMAP, Boc 2 0, THF, room temperature, 2 hours; iii) 10% Pd/C, IM HCl (aq) /ethanol, H 2 (50 psi), 16 hours; iv) EDC, HOBt, NMM, THF, room temperature, 16 hours; and v) TFA/DCM, room temperature 40 minutes. These procedures are more fully described in Examples 104 to 108.
  • Figure 18 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • "i” through “vi” are defined as follows: i) H 2 0/HOAc, Br 2/ NaHC0 3 ; ii) CuCN, DMF, reflux, 20 hours; iii) Boc 2 0, DMAP, THF, room temperature, 2 hours; iv) 10% Pd/C, 1 N HCl/EtOH, H (45 psi) , 16 hours; v) compound (152) , EDC, HOBt, Et 3 N, room temperature, 16 hours; vi) TFA/DCM (1:2), room temperature 25 minutes. These procedures are more fully described in Examples 109 to 114.
  • Figure 19 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • "i” through “iv” are defined as follows: i) Na 2 C0 3 , water, Br 2 , 65°C, 1.5 hours; ii) Cu(I)CN, DMF, reflux, 20 hours; iii) 10% Pd/C, IM HCl (aq) , EtOH, THF, H 2 (20 psi), 16 hours; and iv) compound (152), EDC, HOBt, NMM, room temperature 16 hours.
  • Figure 20 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • "i” through “v” are defined as follows: i) CuCN, DMF, reflux, 20 hours; ii) Boc 2 0, DMAP, THF, room temperature, 2 hours; iii) 10% Pd/C, IM HCl (aq) , EtOH, H 2 (50 psi) , room temperature 16 hours; iv) compound (164) , EDC, HOBt, NMM, THF, room temperature, 16 hours; and v) TFA/DCM (1:1), room temperature 40 minutes. These procedures are more fully described in Examples 119 to 123.
  • Figure 21 depicts a reaction scheme for the synthesis of a compound of the present invention.
  • FIG. 22 depicts a reaction scheme for the synthesis of a compound of the present invention.
  • Figure 23 depicts a reaction scheme for the synthesis of a compound having thrombin inhibitory activity.
  • i through “vii” are defined as follows: i) H 2 S0 4 , methanol, reflux, 20 hours; ii) DHP, pTSA, THF, reflux, 20 hours; iii) LiAH 4 , THF, room temperature, 30 minutes; iv) DPPA, DBU, THF, room temperature, 18 hours; v) LiAlH , THF, room temperature, 30 minutes; vi) EDC, HOAt, NMM, DMF, room temperature, 18 hours; and vii) 3N HCl, THF, 50°C, 18 hours.
  • Figure 24 depicts certain preferred bicyclic E groups .
  • Figures 25A and 25B depict certain compounds of the present invention.
  • Figures 26A to 26C depict certain compounds having thrombin inhibitory activity.
  • (B) Ri is selected from the group consisting of: (1) alkyl of 1 to about 12 carbon atoms which is optionally substituted with Yi and/or Y 2 ,
  • heterocycloalkyl of 4 to about 10 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from the group consisting of oxygen, nitrogen, and S(0)i, wherein i is 0, 1 or 2 , which is optionally mono-, di-, or tri-substituted on the ring with Y l f Y 2 and/or Y 3 ,
  • alkenyl of about 2 to about 6 carbon atoms which is optionally substituted with cycloalkyl of about 3 to about 8 carbon atoms, which is optionally mono-, di-, or tri-substituted on the ring carbons with
  • aryl of about 6 to about 14 carbon atoms which is optionally mono-, di- or tri-substituted
  • heteroaryl of about 5 to about 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally mono-, di-, or tri-substituted with Yi, Y 2 , and/or Y 3 ,
  • aralkyl of about 7 to about 15 carbon atoms which is optionally substituted on the alkyl chain with hydroxy or halogen and mono-, di-, or tri-substituted in the aryl ring with Y lf Y 2 , and/or Y 3 ,
  • heteroaralkyl of 5 to 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally substituted on the alkyl chain with hydroxy or halogen and optionally mono-, di- or tri-substituted on the ring
  • aralkenyl of about 8 to about 16 carbon atoms which is optionally mono-, di-, or trisubstituted on the aryl ring with Y l7 Y 2/ and/or Y 3 ,
  • each Yi, Y 2 , and Y 3 is independently selected from the group consisting of halogen, cyano, nitro, tetrazolyl optionally substituted with alkyl of 1 to about 6 carbon atoms, guanidino, amidino, methylamino, methylguanidino, -CF 3 , -CF 2 CF 3 , -CH(CF 3 ) 2 , -C(OH) (CF 3 ) 2 , -OCF 3 , -OCF 2 CF 3 , -0CF 2 H, -OC(0)NH 2 , -OC(0)NHZ ⁇ , -0C(0)NZ ⁇ Z 2 , -NHC(0)Z ⁇ , -NHC(0)NH 2 , -NHC(0)NHZ ⁇ , -NHC(0) NZ X Z 2 , -C(0)OH, -C(0)OZ ⁇ , -C(0)NH 2 , -C(0)NZ ⁇ Z 2 , -P(0) 3 H 2
  • Yi and Y 2 are selected together to be -0[C(Z 3 ) (Z 4 ) ] r 0- or -0 [C (Z 3 ) (Z 4 ) ] r+i - , wherein r is an integer from 1 to 4 and Z 3 and Z 4 are independently selected from the group consisting of hydrogen, alkyl or 1 to about 12 carbon atoms, aryl of about 6 to about 14 carbon atoms, heteroaryl of about 5 to about 14 ring atoms having 1 to about 9 carbon atoms, aralkyl of about 7 to about 15 carbon atoms, and heteroaralkyl of about 5 to about 14 ring atoms ; (C) D is
  • R 2 is selected from hydrogen, halogen and alkyl of 1 to about 6 carbon atoms
  • R 3 is selected from hydrogen, alkyl of 1 to about 6 carbon atoms, cycloalkyl of 3 to about 7 carbon atoms, alkoxy of 1 to about 5 carbon atoms and trifluoromethyl ;
  • R 4 is hydrogen, alkyl of 1 to about 8 carbon atoms, hydroxy, alkoxy of 1 to about 8 carbon atoms, aralkyl of about 7 to about 15 carbon atoms, alkyl of 1 to about 5 carbon atoms substituted with cycloalkyl of 3 to about 8 carbon atoms, -NHR 5 , -S(0) t R 5 , and C(0)0R 5 ;
  • t 0, 1 or 2;
  • R 5 is hydrogen; alkyl of 1 to about 4 carbon atoms, aryl of about 6 to about 14 carbon atoms which is optionally mono-, di- or tri-substituted with Yi / 2/ and/or Y 3 ; heteroaryl of about 5 to about 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms are selected from oxygen, nitrogen, and sulfur, and which is optionally mono-, di-, or tri-substituted with Y l t Y 2 , and/or Y 3 ; aralkyl of about 7 to about 15 carbon atoms which is optionally substituted on the alkyl chain with hydroxy or halogen and mono-, di-, or tri-substituted in the aryl ring with Yi, Y 2 , and/or Y 3 ; heteroaralkyl of 5 to 14 ring atoms with the ring atoms selected from carbon and heteroatoms, wherein the heteroatoms
  • R 6 is hydrogen or alkyl of 1 to about 3 carbon atoms
  • R 6a and R 6b are independently selected from hydrogen, fluoro, chloro and alkyl of 1 to about 3 carbon atoms
  • R 7a is alkyl of 1 to about 6 carbon atoms, alkoxy of 1 to about 6 carbon atoms, amino, alkylamino of 1 to about 6 carbon atoms or dialkylamino of 2 to about 12 carbon atoms
  • R 7b is hydrogen, acyl, or alkyl of 1 to about 6 carbon atoms
  • Q 7 , Q 8 and Q 9 are independently selected from C(R 6a ), N, S and 0, provided that (i) Q 7 , Q 8 and Q 9 are not all C(R 6a ) and (ii) only one of Q 7 , Q 8 and Q 9 can
  • R 8 and R 9 are independently selected from hydrogen, hydroxy, alkyl of 1 to about 4 carbon atoms, alkyl of 1 to about 4 carbon atoms substituted with alkoxy of 1 to about 4 carbon atoms, alkoxy of 1 to about 6 carbon atoms, halogen and trifluoromethyl;
  • Rn is hydrogen or alkyl of 1 to about 3 carbon atoms;
  • Qi is C(R ⁇ 5 ), C(R ⁇ 6 ) (R 16a ) , N, N(R 15a ), or a direct link;
  • Q 2 is C(R ⁇ s), C(R X7 ) (R 17a ) , N, N(R X5 ),
  • Q 3 is C(R 15 ) , C(R ⁇ ) (R l ⁇ N or N(R ⁇ 5a );
  • Q 4 is C(R 15 ), C(R 19 ) (R 19a ) , N, N(R ⁇ sa),
  • Q 5 is C(R 20 ), C(R 20 ) (R 20a ) or N;
  • Q 6 is C(R 2 ⁇ ), C(R 2 ⁇ ) (R 2 ia) or N;
  • Ris is NR 22 R 23 or -OR 22 ;
  • R ⁇ 5a is hydrogen, alkyl of 1 to about 3 carbon atoms, NR 22a R 23 a or -OR 22a ;
  • R x6 , R 17 , Rig, Rig, R 20/ and R 2i are independently selected from hydrogen, alkyl of 1 to about 3 carbon atoms optionally substituted with alkoxy of 1 to about 3 carbon atoms, alkoxy of 1 to about 4 carbon atoms; halogen and trifluoromethyl;
  • Ri6a i7 a / i ⁇ a Ri9a/ and R2ia are independently hydrogen or absent;
  • R 23 and R 23a are independently hydrogen or alkyl of 1 to about 3 carbon atoms;
  • R 24 is alkyl of 1 to about 6 carbon atoms or alkoxy of 1 to about 6 carbon atoms ; with the provisos that:
  • Preferred X groups include -S(0) 2 -, and a direct link. Especially preferred, according to one aspect, for X is
  • X is a direct link.
  • R x groups include alkyl, substituted aralkyl, aryl, substituted aryl, alkyl substituted with Yi and/or Y 2 and alkyl substituted with optionally substituted cycloalkyl.
  • particularly preferred Ri substituents include substi-tuted or unsubstituted phenyl and substituted or unsubsti-tuted benzyl.
  • Ri is phenyl, 2 , 3-dihydrobenzo- tb] furanyl , or benzyl.
  • Ri is alkyl substitued with Yi and/or Y 2 wherein Yi and Y 2 are independently phenyl or substituted phenyl or alkyl substituted with cycloalkyl which is optionally substituted on the ring with Y x wherein Yi is phenyl or substituted phenyl .
  • Preferred D groups include those where Q is -N- or -C(R 4 )- where R 4 is hydrogen, more preferably Q is -N- .
  • Par-ticularly preferred are D groups where R 2 is hydrogen, especi-ally preferred D groups include those wherein R 3 is methyl .
  • E is a cyclic amino or amidino derivative
  • preferred E groups include the following E groups:
  • Especially preferred E groups include
  • Particularly preferred E groups include
  • Preferred compounds according to this aspect of the present invention include those wherein Ri is benzyl, substituted benzyl, phenyl, substituted phenyl; alkyl substituted with Yi and/or Y 2 wherein, preferably, Yi and Y 2 are independently phenyl or substituted phenyl, or alkyl substituted with cycloalkyl which is optionally substituted with Yi wherein Yi is preferably phenyl or substituted phenyl.
  • Especially preferred substituted phenyl groups include 2 , 3-dihydrobenzofuran-5-yl .
  • X is -S(0) 2 - or a direct link.
  • Ri is preferably benzyl, subsituted benzyl, phenyl or substituted phenyl, more particularly 2 , 3-dihydrobenzofuran-5-yl .
  • Ri is preferably alkyl mono- or di-substituted with phenyl or substituted phenyl or alkyl substituted with cycloalkyl which is substituted on the ring with phenyl or substituted phenyl.
  • preferred E groups include:
  • Especially preferred E groups include
  • Preferred compounds according to this aspect include those having D groups where Q is -N- or -C(H)-, more preferably Q is -N- .
  • Preferred R 2 groups include hydrogen.
  • Preferred R 3 groups include hydrogen and methyl, especially preferred is methyl.
  • Particularly preferred E groups include
  • preferred compounds include those having D groups where Q is -N- or -C(H)-, more preferably Q is -N- .
  • E is preferably selected from:
  • Especially preferred compounds according to this aspect include those wherein R 2 is hydrogen, R 3 is methyl, and J is selected from
  • Especially preferred J groups include
  • Particularly preferred E groups include
  • preferred compounds include those wherein J is selected from
  • R 6 , R ⁇ a R ⁇ b and R 7 are hydrogen, More preferably, J is selected from:
  • preferred for X is -S(0) 2 - or a direct link.
  • Preferred R 1 groups include benzyl, substituted benzyl, phenyl, substituted phenyl, alkyl substituted with Yi and/or Y 2 wherein Y x and Y 2 are preferably phenyl or substituted phenyl, or alkyl optionally substituted with Yi wherein Y x is preferably phenyl or substituted phenyl.
  • preferred E groups include:
  • Preferred compounds according to this aspect include those having D groups where Q is -N- , especially preferred are those D groups wherein R 2 is hydrogen and R 3 is methyl.
  • R 6 groups include hydrogen, and alkyl of 1 to 3 carbon atoms. Especially preferred are compounds wherein R 6 is hydrogen.
  • Preferred E groups include those wherein Qi is a direct link.
  • Q 2 is C(R ⁇ 5 ) or C(R i7 ) (R ⁇ 7a ) , Q 3 is N and Q 4 is N;
  • Q 2 is C(Ri 5 ) or C (R x7 ) (R ⁇ 7a ) , Q 3 is C(R ⁇ 8 ) (Ri ⁇ a) and Q is N;
  • Q 2 is 0, Q 3 is N and Q 4 is C(R ⁇ 5 );
  • Q 2 is N, Q 3 is N and Q 4 is C(R ⁇ 5 ) or
  • Q 2 is N, Q 3 is C(R ⁇ 5 ) or C(R ⁇ 8 ) (Ri ⁇ a) , and Q is N.
  • Especially preferred E groups include those where Q 6 is C(R 2i ) or C(R 2i ) (R 2 ia) • According to one aspect of the present invention, preferred compounds include the following E groups:
  • Especially preferred E groups include
  • Preferred compounds according to one aspect of the present invention include those wherein Ri is benzyl, substituted benzyl, phenyl, substituted phenyl; alkyl substituted with Yi and/or Y 2 wherein, preferably, Yi and Y 2 are independently phenyl or substituted phenyl, or alkyl substituted with cycloalkyl which is optionally substituted with Yi wherein Y is preferably phenyl or substituted phenyl.
  • Especially preferred substituted phenyl groups include 2 , 3-dihydrobenzofuran-5-yl .
  • X is -S(0) 2 - or a direct link.
  • Ri is preferably benzyl, subsituted benzyl, phenyl or substituted phenyl, more particularly 2 , 3-dihydrobenzofuran-5-yl .
  • R x is preferably alkyl mono- or di- substituted with phenyl or substituted phenyl or alkyl substituted with cycloalkyl which is substituted on the ring with phenyl or substituted phenyl.
  • preferred E groups include:
  • Especially preferred E groups include
  • Preferred compounds according to this aspect include those having D groups where Q is -N- or -C(H)-, more preferably Q is -N- .
  • Preferred R 2 groups include hydrogen.
  • Preferred R 3 groups include hydrogen and methyl, especially preferred is methyl.
  • preferred compounds include those having D groups where Q is -N- or -C(H)-, more preferably Q is -N- .
  • E is preferably selected from those groups wherein Qi is a direct link and (a) Q 2 is C(R ⁇ 5 ) or C(R ⁇ v) (Ri7a) , Qs s N and Q 4 is N; (b) Q 2 is C(R ⁇ 5 ) or C(R i7 ) (R 17a ) , Q 3 is C(R ⁇ ) (Ri ⁇ a) and Q 4 is N; (c) Q 2 is 0, Q 3 is N and Q 4 is C(R ⁇ 5 ) ; (d) Q 2 is N, Q 3 is N and Q 4 is C(R ⁇ s) or (e) Q 2 is N, Q 3 is C(R ⁇ 5 ) or C (R i8 ) (R 18a ) , and Q 4 is N.
  • E groups include those where Q 6 is C(R ⁇ 5 ) or C(R ⁇ v
  • Especially preferred compounds according to this aspect include those wherein R is hydrogen, R 3 is methyl, and J is
  • E is
  • R 6 groups include hydrogen, and alkyl of 1 to 3 carbon atoms. Especially preferred are compounds wherein R 6 is hydrogen.
  • Preferred E groups according to this aspect include those wherein (a) Qi is N or C(R ⁇ 6 ) (R ⁇ 6a ) (b) Q 2 is N, C(Ri 5 ), or C(R ⁇ 7 ) ( Riva); (c) Q 3 is N, C(R 15 ) or C ( R ⁇ 8 ) ( R ⁇ ⁇ a ) and Q 4 is N, C(R ⁇ 5 ) or C(R ⁇ 9 ) (R ⁇ 9a ) where R ⁇ 5 is preferably N R 22 R 23; Ri6/ Ri7, Ri ⁇ , 19, R22 and R 23 are preferably hydrogen and R ⁇ 6a , R ⁇ 7a , Ri ⁇ a and R ⁇ 9a are preferably absent.
  • Q 5 is C(R 20 ) and Q 6 is C(R 2i ) where R 20 and R 2i are preferably hydrogen. More preferably, (a) Qi is N, Q 2 is N, and one of Q 3 and Q 4 is N and the other is C(R ⁇ 5 ); (b) Qi is N, Q 3 is C(R ⁇ 8 ) (Ri ⁇ a) and one of Q 2 and Q 4 is N and the other is C(R ⁇ 5 ); (c) Qi is N, Q 2 is C(R ⁇ 5 ) or C(R ⁇ 7 ) (Ri7a) / Q3 is N and Q 4 is C(R ⁇ 5 ) or C(R ⁇ 9 ) (R ⁇ 9a ) ; (d) Qi is C(R ⁇ 6 ) (R ⁇ 6a ) one of Q 2 and Q 4 is N and the other is C(R ⁇ 5 ) and Q 3 is N; (e) Qi is N, Q 2 is C(R i5 ) or C(R ⁇ 7 )
  • preferred compounds include those where E is selected from the groups depicted in Figure 24.
  • Q 6 is preferably C(R 2i ) or C(R 2 ⁇ ) (R 2 ia) • More preferably Q 5 is C(R 20 ) or C(R 20 ) (R 20a ) •
  • Preferred compounds of the present invention include those depicted in Figures 8, 9, 16, 21, 22, 25A to 25B.
  • the compounds of the present invention may have chiral centers and occur as racemates, racemic mixtures and as individual diastereomers, or enantiomers with all isomeric forms being included in the present invention.
  • the compounds of the present invention may also have polymorphic crystalline forms, with all polymorphic crystalline forms being included in the present invention.
  • the bond attached to the variable is not present, for example, with the group — ( ⁇ ) n if n is 0, then the single bond that would attach to R 6 is also not present.
  • Description of compounds of the present invention are limited by principles of chemical bonding known to those skilled in the art.
  • variables R 2 , X, D and J may be purchased from commercially available sources such as Sigma, Fluka, Aldrich, Nova and Calbiochem or synthesized by one skilled in the art. See, e . g. , Owens, T. D. ; Semple, J. E. Bioorg. Med. Chem . Lett . 1998, 8 , 3683. Semple, J. E.; Rowley, D. C . ; Owens, T. D.; Minami, N. K. ; Uong, T. H.; Brunck, T. K. ibid .
  • R ⁇ ⁇ may be purchased from commercially available sources such as Sigma, Fluka, Aldrich, Nova and Calbiochem or synthesized by one skilled in the art. See, e . g. , Sanderson, P. E. J., et al . , J. Med . Chem . 1998, 41 , 4466-4474; Miller, W. D.; Tao, E. V. P. USP (1995) 5,387,681.
  • Preferred means of chemically coupling include formation of a peptide bond by using conventional coupling reagents known in the art. See Bodanszky, N., Peptide Chemistry, pp. 55-73, Springer-Verlag, New York (1988) and references cited therein.
  • the chemical coupling may be either by means of one-step or two-step coupling. In one-step coupling, the two coupling partners are coupled directly.
  • Preferred coupling reagents for one-step coupling of the include DCC with HOBt, EDC with HOBt,
  • HBTU or TBTU In two-step coupling, an activated ester or anhydride of the C-terminal carboxy group of one coupling partner is formed prior to its coupling to the other coupling partner.
  • an activated ester or anhydride of the C-terminal carboxy group of one coupling partner is formed prior to its coupling to the other coupling partner.
  • Another preferred method for preparing compounds of the present invention containing hydrogenation sensitive groups such as alkenyl or aryl moieties substituted with halogen, cyano, nitro, or -S-Z lf is to use boron tris (trifluoroacetate) , B(OCOCF 3 ) 3 , to cleave protecting groups such as the N 9 -nitro of an arginine side chain.
  • the reagent is prepared by the reaction of BBr 3 and CF 3 C00H in dichloromethane at 0°C
  • the reagent is also commercially available.
  • the N 9 -nitro compound is treated with boron tris (trifluoroacetate) in trifluoroacetic acid at 0°C .
  • boron tris trifluoroacetate
  • titanium trichloride is another preferred reagent for 0 selective nitro group cleavage.
  • This reagent is commercially available.
  • the N 9 nitro compound is treated with titanium trichloride in aqueous methanol containing an ammonium acetate buffer followed by exposure of the reaction mixture to air or dimethyl 5 sulfoxide.
  • the compounds of the present invention are screened for their ability to inhibit some or all of thrombin, factor Xa, plasmin, recombinant tissue plasminogen activator (rt-PA) , activated protein C (aPC) , chymotrypsin, and trypsin as set forth below. Certain of the preferred compounds are distinguished by their ability to inhibit thrombin, while not substantially ⁇ inhibiting some or all of plasmin, tissue plasminogen activator (t-PA) , activated protein C (aPC) , chymotrypsin, and trypsin.
  • the term "not substantially inhibiting" means that the IC 50 (or Ki) for 0 plasmin, t-PA, aPC, chymotrypsin, and trypsin for a given compound is greater than or equal to its IC 50 (or Ki, respectively) for thrombin.
  • the ratio of IC 50 's for plasmin, and the other enzymes, to IC 50 for thrombin will be at least about 25 or greater, more preferably about 100 or greater. It is believed that the ability to selectively inhibit thrombin will result in therapeutic benefits to patients.
  • not specifically inhibiting means the IC 50 or Ki for the target enzyme is less than or equal to the IC 50 or Ki for non-target enzymes contacted with the inhibitor.
  • the compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from 0 to 100 micromolar.
  • concentrations such that assay concentrations range from 0 to 100 micromolar.
  • a chromogenic synthetic substrate is added to a solution containing test compound and the enzyme of interest and the residual catalytic activity of that enzyme is determined spectrophometrically .
  • the IC 50 of a compound of the present invention is determined from the rate of substrate turnover caused by the specific enzyme being measured.
  • IC 50 is the concentration of test compound which gives 50% inhibition of the rate of substrate turnover.
  • the Ki of a compound of the present invention is determined from the rate of substrate turnover caused by the specific enzyme being measured at various enzyme concentrations.
  • Example A provides exemplars of in vi tro assays used to select the compounds of the present invention.
  • Certain of the preferred compounds of the present invention have a Ki of about 0.001 to about 200 nM in the thrombin assay. Especially preferred compounds have a Ki of about 0.001 to about 50 nM. The more especially preferred compounds have a Ki of about 0.001 to about 10 nM.
  • Certain of the preferred compounds of the present invention have a IC 50 for plasmin, t-PA, aPC, chymotrypsin, and trypsin which is at least 10 times greater than its IC 50 for thrombin.
  • Especially preferred compounds have an IC 50 for plasmin, t-PA, aPC, chymotrypsin, and trypsin which is about 20 to about 100,000 times greater than its IC 50 for thrombin. More especially preferred compounds have an IC 50 for plasmin, t-PA, aPC, chymotrypsin, and trypsin which is about 100 to about 1,000,000 times greater than its IC 50 for thrombin.
  • a compound of the present invention has an IC 50 with respect to plasmin, t-PA, aPC, chymotrypsin, or trypsin which is greater than the highest concentration of compound tested, the highest concentration of compound tested is considered to be the reported IC 50 .
  • the compounds of the present invention are dissolved in buffer to give solutions containing concentrations such that assay concentrations range from 0 to 100 micromolar.
  • a chromogenic synthetic substrate is added to a solution containing test compound and the enzyme of interest, and the residual catalytic activity of that enzyme is determined spectrophotometrically.
  • the IC 50 of a compound of the present invention is determined from the rate of substrate turnover caused by the specific enzyme being measured. IC 50 is that concentration of test compound giving 50% inhibition of the rate of substrate turnover.
  • the Ki of a compound of the present invention is determined from the rate of substrate turnover caused by the specific enzyme being measured at various enzyme concentrations.
  • Example A provides an example of the in vi tro assays used to select the preferred compounds of the present invention.
  • Example A provides a method for identifying and selecting compounds of the present invention that inhibit thrombin, plasmin, t-PA, aPC, chymotrypsin and trypsin to a greater extent than they inhibit factor Xa and, thus, have utility as inhibitors of those proteases.
  • the present invention encompasses pharmaceutical compositions prepared for storage or administration which comprise a therapeutically effective amount of a compound of the present invention in a pharmaceutically acceptable carrier.
  • the therapeutically effective amount of a compound of the present invention will depend on the route of administration, the type of mammal being treated, and the physical characteristics of the specific mammal under consideration. These factors and their relationship to determining this amount are well known to skilled practitioners in the medical arts. This amount and the method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight , diet , concurrent medication and other factors which those skilled in the medical arts will recognize.
  • the therapeutically effective amount of the compound of the present invention can range broadly depending upon the desired affects and the therapeutic indication. Typically, dosages will be between about 0.01 mg/kg and 100 mg/kg body weight, preferably between about 0.01 and 10 mg/kg, body weight.
  • Pharmaceutically acceptable carriers for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington' s Pharmaceutical Sciences, Mack Publishing Co. (A.R.
  • Gennaro edit. 1985 sterile saline and phosphate-buffered saline at physiological pH may be used.
  • Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition.
  • sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid may be added as preservatives. Id . at 1449.
  • antioxidants and suspending agents may be used. Id.
  • compositions of the present invention may be formulated and used as tablets, capsules or elixirs for oral administration; suppositories for rectal administration; sterile solutions and suspensions for injectable administration; and the like.
  • the dose and method of administration can be tailored to achieve optimal efficacy but will depend on such factors as weight, diet, concurrent medication and other factors which those skilled in the medical arts will recognize.
  • injectable pharmaceutical compositions can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution or suspension in liquid prior to injection, or as emulsions.
  • Suitable excipients are, for example, water, saline, dextrose, mannitol , lactose, lecithin, albumin, sodium glutamate, cysteine hydrochloride, or the like.
  • the injectable pharmaceutical compositions may contain minor amounts of nontoxic auxiliary substances, such as wetting agents, pH buffering agents, and the like. If desired, absorption enhancing preparations (e.g., liposomes) may be utilized.
  • Compounds of the present invention when made and selected as disclosed are useful as potent inhibitors of thrombin in vi tro and in vivo .
  • these compounds are useful as in vi tro diagnostic reagents to prevent the clotting of blood and as in vivo pharmaceutical agents to prevent, inhibit and/or attenuate thrombosis in mammals suspected of having a condition characterized by abnormal thrombosis.
  • the compounds of the present invention are useful as in vi tro diagnostic reagents for inhibiting clotting in blood drawing tubes .
  • the use of stoppered test tubes having a vacuum therein as a means to draw blood obtained by venipuncture into the tube is well known in the medical arts.
  • Such vacuum tubes may be free of clot-inhibiting additives, in which case, they are useful for the isolation of mammalian serum from the blood. They may alternatively contain clot- inhibiting additives (such as heparin salts, EDTA salts, citrate salts or oxalate salts) , in which case, they are useful for the isolation of mammalian plasma from the blood.
  • clot- inhibiting additives such as heparin salts, EDTA salts, citrate salts or oxalate salts
  • the compounds of the present invention are potent inhibitors of thrombin, and as such, can be incorporated into blood collection tubes to prevent clotting of the mammalian blood drawn into them.
  • the compounds of the present invention are used alone, in combination with other compounds of the present invention, or in combination with other known inhibitors of clotting, in the blood collection tubes.
  • the amount to be added to such tubes is that amount sufficient to inhibit the formation of a clot when mammalian blood is drawn into the tube.
  • the addition of the compounds to such tubes may be accomplished by methods well known in the art, such as by introduction of a liquid composition thereof, as a solid composition thereof, or liquid composition which is lyophilized to a solid.
  • the compounds of the present invention are added to blood collection tubes in such amounts that, when combined with 2 to 10 mL of mammalian blood, the concentration of such compounds will be sufficient to inhibit clot formation. Typically, the required concentration will be about 1 to 10,000 nM, with 10 to 1000 nM being preferred.
  • the compounds of the present invention are useful as a pharmaceutical agent for preventing, inhibiting and/or attenuating thrombosis in a mammal suspected of having a condition characterized by abnormal thrombosis.
  • Conditions characterized by abnormal thrombosis are well known in the medical arts and include those involving the arterial and venous vasculature of mammals.
  • abnormal thrombosis (thrombus formation) characterizes the rupture of an established atherosclerotic plaque which is the major cause of acute myocardial infarction and unstable angina, as well as also characterizing the occlusive coronary thrombus formation resulting from either thrombolytic therapy or percutaneous transluminal coronary angioplasty (PTCA) .
  • thrombosis characterizes the condition observed in patients undergoing major surgery in the lower extremities or the abdominal area who often suffer from thrombus formation in the venous vasculature resulting in reduced blood flow to the affected extremity and a predisposition to pulmonary embolism.
  • Abnormal thrombosis further characterizes disseminated intravascular coagulopathy which commonly occurs within both vascular systems during septic shock, certain viral infections and cancer, a condition wherein there is rapid consumption of coagulation factors and systemic coagulation which results in the formation of life-threatening thrombi occurring throughout the microvasculature leading to widespread organ failure.
  • the present invention includes methods for preventing a condition in a mammal suspected of having a condition characterized by abnormal thrombosis, comprising administering to said mammal a therapeutically effective amount of a compound or a pharmaceutical composition of the present invention.
  • the compounds or pharmaceutical compositions of the present invention are administered in vivo, ordinarily in a mammal, preferably in a human.
  • the compounds or pharmaceutical compositions can be administered to a mammal in a variety of ways, including orally, parenterally, intravenously, subcutaneously, intramuscularly, colonically, rectally, nasally or intraperitoneally, employing a variety of dosage forms.
  • Administration is preferably parenteral, such as intravenous on a daily basis.
  • administration is preferably oral, such as by tablets capsules or elixirs taken on a daily basis.
  • the compounds or pharmaceutical compositions of the present invention are administered alone or in combination with one another, or in combination with other therapeutic or in vivo diagnostic agents.
  • a "therapeutically effective amount" of the compounds or pharmaceutical compositions of the present invention will vary depending upon the age, weight and mammalian species treated, the particular compounds employed, the particular mode of administration and the desired affects and the therapeutic indication. Because these factors and their relationship to determining this amount are well known in the medical arts, the determination of therapeutically effective dosage levels, the amount necessary to achieve the desired result of preventing thrombosis, will be within the ambit of one skilled in these arts. Typically, administration of the compounds or pharmaceutical composition of the present invention is commenced at lower dosage levels, with dosage levels being increased until the desired effect of preventing in vivo thrombosis is achieved which would define a therapeutically effective amount. For the compounds of the present invention, alone or as part of a pharmaceutical composition, such doses are between about 0.01 mg/kg and 100 mg/kg body weight, preferably between about 0.01 and 10 mg/kg, body weight.
  • Certain compounds of the present invention have utility as inhibitors of proteases within the trypsin/chymotrypsin class of enzymes.
  • Members of that class include, but are not limited to, elastase, chymotrypsin, and the serine proteases trypsin, thrombin, factor Xa, and factor Vila.
  • the inhibitors within the present invention directed at serine proteases acting within the coagulation cascade e . g. , inhibitors of thrombin, factor Xa and factor Vila, such have in vi tro and in vivo utilities as provided hereinabove for thrombin inhibitors.
  • Elastase has been implicated in a variety of conditions, including pulmonary hypertension (Rabinovitch, M. , Acta Paediatr. Jpn 37 : 657-666 (1995)), idiopathic pulmonary fibrosis, rheumatoid arthritis, adult respiratory distress syndrome, cystic fibrosis, and other inflammatory diseases and conditions (Doring, G., Am . J. Respir . Cri t . Care Med . 150 : S114-S117 (1994)) . Inhibition of elastase was shown to prevent or retard progression of pulmonary hypertension (Rabinovitch) .
  • inhibitors of the present invention directed toward elastase are useful as pharmaceutical compositions for the inhibition of elastase in conditions where elastase activity is associated with a pathological condition.
  • Elevated levels of chymotrypsin and trypsin are associated with the pathological effects resulting from pancreatitis (see US 5,534,498).
  • Animal studies of chemically- induced pancreatitis suggest that the disorder is rooted in the inability of pancreatic acinar cells to excrete digestive proenzymes, resulting in activation of trypsinogen to trypsin by lysosomal hydrolases within the cell. The amount of trypsin produced exceeds protective levels of protease inhibitor normally available.
  • pancreatitis which is characterized by damage to the pancreas and surrounding tissues from autodigestion of the cells by the various digestive enzymes.
  • These activated digestive enzymes also cause edema, interstitial hemorrhage, vascular damage, coagulation necrosis, fat necrosis and parenchymal cell necrosis.
  • Inhibitors of the present invention directed toward either trypsin or chymotrypsin, or other members of the trypsin/chymotrypsin family that contribute to the deleterious effects of pancreatitis, are useful for the prevention and treatment of pancreatitis in mammals.
  • inhibitors of the present invention also find utility in vi tro.
  • Inhibitors of enzymes within the coagulation cascade are useful inhibitors of blood coagulation in vi tro, as described hereinabove.
  • Inhibitors of other enzymes within the trypsin/chymotrypsin family, including trypsin, chymotrypsin, and elastase are useful reagents in in vi tro assays designed to measure the activity of such enzymes .
  • the activity of the enzyme in the sample is determined in the presence and absence of the specific inhibitor (which may be labeled using a radioactive or other detectable label) .
  • the specific inhibitor which may be labeled using a radioactive or other detectable label.
  • Lower activity measured in the presence of inhibitor as compared to in the absence of inhibitor demonstrates inhibition of the enzyme and, thus, its presence in the sample.
  • the level of activity of an enzyme present in a sample is determined by adding inhibitor to the sample in a range of titrating doses, and calculating activity of the enzyme at each escalating dose of inhibitor.
  • concentration of inhibitor that completely inhibits the enzyme in the assay along with knowledge of the assay parameters and characteristic of enzyme inhibition, allows one to calculate the activity of the enzyme in the sample.
  • Chymotrypsin inhibitors of the present invention are useful in such assays to evaluate the level of active chymotrypsin in such a sample, according to protocols such as those outlined hereinabove.
  • an additional use of the inhibitors of the present invention is their use to quench enzymatic reactions effected by the target enzyme.
  • an inhibitor of trypsin or chymotrypsin, respectively is added in inhibit the target enzyme and, thus, control or prevent digestion by that enzyme.
  • Certain compounds of the present invention can also be useful inhibitors of elastase, and are therefore useful pharmaceutical agents for the control of inflammation.
  • reaction mixture was diluted with methylene chloride (600 mL) and washed with saturated NaHC0 3 aqueous solution (300 mL) , water (300 mL) and brine (50 mL) . After drying (Na 2 SO Register) , the organic solvent was removed under vacuum to give a yellow oil which was purified by a flash chromatography on silica gel (85:15 hexane-ethyl acetate) to yield the title compound (4) (10.01 g, 95%).
  • This intermediate was further treated with hydrogen chloride in dioxane (Aldrich, 4M, 2 mL) at 60 °C for 1 hour.
  • the reaction mixture was purified on a reversed phase preparatory HPLC eluting with acetonitrile-0.1% of TFA 5 in water. Lyophilization under high vacuum afforded a white solid (9 mg, 6%). HPLC retention, 15.5 minutes; C18 column 5-75% acetonitrile in water over 25 minutes, 1.0 mL/min.
  • the crude product was purified by reversed phase preparatory HPLC, eluting with an acetonitrile-0.1% TFA in water system. The pure fractions were concentrated and lyophilized to provide the title compound as a white solid (488 mg, 99% purity, 51% yield).
  • the reaction mixture was extracted with ethyl acetate. The combined extracts were washed ° with brine and then dried over Na 2 S0 4 . After filtration and evaporation, the crude product was purified on a silica gel column, eluting with hexane-ethyl acetate (4:1 and 3:1). The product 68 was obtained as colorless oil (1.05 g, 24% yield).
  • the product was extracted with dichloromethane, and the combined extracts were washed by saturated aqueous NaHC0 3 and brine, and dried over Na 2 S0 4 .
  • the crude product was purified on a silica gel column eluting with hexane-ethyl acetate (from 4:1 to 1:1) .
  • the product (120 mg) obtained was contaminated with butylboronic acid.
  • This mixture was dissolved in ether (10 mL) .
  • To the ether solution was added 2N NaOH solution (3 mL) , and the mixture was stirred at room temperature overnight. The layers were separated, and the organic layer was washed with brine and dried over Na 2 S0 4 .
  • the mixture was diluted with ethyl acetate, washed with IM KHS0 4 solution, saturated aqueous NaHC0 3 and brine, and then dried over Na 2 S0 4 . After filtration and evaporation, the crude products were purified on a silica gel column eluting with hexane-ethyl acetate (from 4:1 to 1:1). The first fraction was compound 72 (6.0 mg, 9.6% yield) which was obtained as a white foaming solid.
  • Example 9 substituting 1 , 3-benzodioxole for 2,3- dihydrobenzofuran.
  • Intermediate 93 was converted to compound 94 using the same reaction sequences described i Examples 10 and 11.
  • reaction mixture was diluted with water, filtered through a 2 micro-filter, and purified using reversed phase preparatory HPLC eluting with an acetonitrile-0.1% of TFA in water system. Those fractions of >90% purity were combined and concentrated. Lyophilization under high vacuum (0.1 mm Hg) for 48 hours afforded a white solid (compound 95, 117 mg, 16%) .
  • reaction mixture was diluted with water, filtered through a 2 micro-filter, and purified using reversed phase preparatory HPLC eluting with an acetonitrile-0.1% of TFA in water system. Those fractions of >90% purity were combined and concentrated. Lyophilization under high vacuum (0.1 mm Hg) for 48 hours afforded a white solid (compound 98, 242 mg, 46%).
  • reaction mixture was diluted with water, filtered through a 2 micro-filter, and purified using reversed phase preparatory HPLC eluting with an acetonitrile-0.1% of TFA in water system. Those fractions of >90% purity were combined and concentrated. Lyophilization under high vacuum (0.1 mm Hg) for 48 hours afforded a white solid (compound 62, 109 mg, 56%) .
  • reaction mixture was diluted with water, filtered through a 2 micro-filter, and purified 0 using reversed phase preparatory HPLC eluting with an acetonitrile-0.1% of TFA in water system. Those fractions of >90% purity were combined and concentrated. Lyophilization under high vacuum (0.1 mm Hg) for 48 hours afforded a white solid (compound 103, 332 mg, 51%) .
  • the intermediate 114 was synthesized using the reaction procedures which are described in Examples 9, 10 and 11, substituting 2 -methyl-2 , 3-dihydrobenzofuran (TCI chemicals, Inc.) for 2 , 3-dihydrobenzofuran (in Example 9) .
  • reaction mixture was treated with 4M HCl in dioxane (Aldrich) at 0 60°C for 2 hours, followed by purification using reversed phase preparatory HPLC eluting with an acetonitrile-0.1% TFA in water system. Lyophilization under high afforded the product (121) as a white solid (101 mg, 3.9%).
  • the reaction mixture was then poured into 700 mL ice water and let to warm to room temperature.
  • the aqueous solution was extracted 3 times with 250 mL toluene.
  • the organic phases were combined and dried over anhydrous sodium sulfate.
  • the sodium sulfate was filtered away and the organic layer was concentrated to remove the acetone.
  • the resulting solution of toluene was heated to 65 °C for 16 hours.
  • the reaction mixture was cooled to room temperature and was then concentrated under vacuum. The remaining residue was dissolved in 100 mL acetonitrile. Once a homogeneous solution formed, 100 mL (100 mmol) of IN NaOH was added. The resulting solution was stirred for 1 hour at room temperature.
  • Example 100 The compound of Example 100 (136) (13.6 g, 34.65 mmol) was dissolved in 50 mL 50% trifluoroacetic acid in dichloromethane and stirred at room temperature for 4 hours. The solvent was evaporated under vacuum. A solution of dichloromethane and toluene was added as an azeotrope. The solution was concentrated under vacuum to afford 13.6 g of the above- identified product (137) as a light brown solid.
  • Example 101 The compound of Example 101 (137) (0.336 g, 1 mmol) was dissolved in 5 mL anhydrous dimethylformamide under a nitrogen atmosphere at room temperature. To the reaction mixture was added 0.149 g (1.1 mmol) 1-hydroxy- 7-azabenzotriazole and 0.210 g (1.1 mmol) l-ethyl-3- (3 ' - dimethylaminopropyl) carbodiimide hydrochloride. The solution was stirred until homogeneous and then compound of Example 98 (130) (0.284 g, 1 mmol) was added. The reaction mixture was stirred for 16 hours at room temperature.
  • the intermediate, uncyclized product had a retention time of 15.4 minutes.
  • the reaction mixture was heated to 95°C for 2 hours.
  • the reaction mixture was then cooled to room temperature and was diluted with 200 mL of ethyl acetate.
  • the organic solution was washed with 100 mL of water, saturated aqueous sodium bicarbonate, brine, and dried over anhydrous sodium sulfate.
  • a solution of activated zinc dust was prepared by adding 0.612 g (9.36 mmol) zinc dust to 3 mL 0.5N hydrochloric acid and stirring for 5 minutes. The solution was decanted and washed with water and methanol. A portion of the activated zinc (300 mg, 4.6 mmol) was added to a solution of the compound Example 104 (138) (0.140 g, 0.234 mmol) in 5 mL 80% acetic acid in water. The reaction was quenched after 5 minutes by adding 15 mL water. The reaction mixture was filtered and washed with an additional 10 mL of water.
  • the desired fractions were collected, the acetonitrile was removed under vacuum, and the aqueous solution was frozen and lyophilized to afford 1.5 mg of the above- identified 0 product (139) as a white solid.
  • Analytical HPLC retention time 12.1 minutes, (15 to 60% acetonitrile in water with 0.1 % trifluoroacetic acid over 20 minutes) .
  • Example 107 The compound of Example 107 (145) (300 mg, 0.47 mmol) was added with a solution of TFA and methylene chloride (1:1, 20 mL) . The resulting mixture was stirred at room temperature for 40 minutes. After removal of solvent, the residue was subjected to preparative HPLC purification eluting with an acetonitrile-0.1% TFA in water system. The pure fractions were concentrated and lyophilized to provided a white solid product (146) (93 mg, 45%). MS: m/e 443(M+H) + .
  • X H NMR 400 MHz, CD 3 0D) : ⁇
  • (164) may be prepared according to the procedures described in Examples 7 and 89 of commonly-assigned United States Patent No. 5,658,930.
  • rt-PA tissue plasminogen activator
  • the buffer used for all assays was HBSA (10 mM HEPES, pH 7.5, 150 mM sodium chloride, 0.1% bovine serum albumin) .
  • the assay for IC 50 determinations was conducted by combining in appropriate wells of a Corning microtiter plate, 50 microliters of HBSA, 50 microliters of the test compound at a specified concentration (covering a broad concentration range) diluted in HBSA (or HBSA alone for V 0 (uninhibited velocity) measurement) , and 50 microliters of the enzyme diluted in HBSA. Following a 30 minute incubation at ambient temperature, 50 microliters of the substrate at the concentrations specified below were added to the wells, yielding a final total volume of 200 microliters.
  • the initial velocity of chromogenic substrate hydrolysis was measured by the change in absorbance at 405 nm using a Thermo Max ® Kinetic Microplate Reader over a 5 minute period in which less than 5% of the added substrate was utilized.
  • the concentration of added inhibitor which caused a 50% decrease in the initial rate of hydrolysis was defined as the IC 50 value.
  • Enzyme activity was determined using the chromogenic substrate, Pefachrome t-PA
  • IC 50 determinations were conducted where HBSA (50 ⁇ L) , ⁇ -thrombin (50 ⁇ l) (the final enzyme concentration is 0.5 nM) and inhibitor (50 ⁇ l) (covering a broad concentration range) , were combined in appropriate wells and incubated for 30 minutes at room temperature prior to the addition of substrate Pefachrome-t-PA (50 ⁇ l) (the final substrate concentration is 250 ⁇ M, about 5 times Km) .
  • the initial velocity of Pefachrome t-PA hydrolysis was measured by the change in absorbance at 405nm using a Thermo Max ® Kinetic Microplate Reader over a 5 minute period in which less than 5% of the added substrate was utilized.
  • the concentration of added inhibitor which caused a 50% decrease in the initial rate of hydrolysis was defined as the IC 50 value.
  • rt-PA tissue plasminogen activator
  • Plasmin catalytic activity was determined using the chromogenic substrate, S-2366 [L-pyroglutamyl-L-prolyl-L-arginine-p-nitroaniline hydrochloride], which was obtained from DiaPharma group.
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 300 micromolar (about 2.5-times Km).
  • Purified human plasmin was obtained from Enzyme Research Laboratories, Inc. The enzyme was diluted into HBSA prior to assay in which the final concentration was 1.0 nM.
  • Activated Protein C (aPC) Assay aPC catalytic activity was determined using the chromogenic substrate, Pefachrome PC (delta-carbobenzloxy-D- lysine-L-prolyl-L-arginine-p-nitr oaniline dihydrochloride) , obtained from Pentapharm Ltd.) .
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 400 micromolar (about 3-times Km) .
  • Purified human aPC was obtained from Hematologic Technologies, Inc. The enzyme was diluted into HBSA prior to assay in which the final concentration was 1.0 nM. Chymotrypsin Assay
  • Chymotrypsin catalytic activity was determined using the chromogenic substrate, S-2586 (methoxy- succinyl-L-arginine-L-prolyl-L-tyrosyl-p-nitroanilide) , which was obtained from DiaPharma Group.
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 100 micromolar (about 9-times Km) .
  • Purified (3X- crystallized; CDI) bovine pancreatic alpha-chymotrypsin was obtained from Worthington Biochemical Corp.
  • the enzyme was reconstituted in deionized water and diluted into HBSA prior to assay in which the final concentration was 0.5 nM.
  • the substrate was made up in deionized water followed by dilution in HBSA prior to the assay in which the final concentration was 250 micromolar (about 4-times Km) .
  • the enzyme was reconstituted in deionized water and diluted into HBSA prior to assay in which the final concentration was 0.5 nM.
  • Table I lists the determined IC 50 values for certain of the enzymes listed above for certain compounds of the present invention (depicted in Figures 25A and 25B) and demonstrate the high degree of specificity for the inhibition of alpha-thrombin compared to these related serine proteases.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés comprenant un cycle de pyrazinone ou de pyridinone en position P3 et se caractérisant par la présence d'un dérivé amino ou amidino cyclique en position P1. Ces composés présentent une puissante activité biologique en tant qu'inhibiteurs de la thrombine. L'invention concerne également leurs sels pharmaceutiquement acceptables, leurs compositions pharmaceutiques et des méthodes d'utilisation desdits composés, ainsi que des compositions pharmaceutiques renfermant ces composés en tant qu'agents thérapeutiques destinés au traitement d'états pathologiques chez des mammifères présentant une thrombose anormale.
PCT/US2001/012276 2000-04-14 2001-04-13 Nouveaux inhibiteurs de thrombine de type non covalent WO2001079195A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001255399A AU2001255399A1 (en) 2000-04-14 2001-04-13 Pyridine and pyrazine derivatives as thrombin inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54945200A 2000-04-14 2000-04-14
US55009300A 2000-04-14 2000-04-14
US09/549,452 2000-04-14
US09/550,093 2000-04-14

Publications (3)

Publication Number Publication Date
WO2001079195A2 WO2001079195A2 (fr) 2001-10-25
WO2001079195A3 WO2001079195A3 (fr) 2002-05-16
WO2001079195A9 true WO2001079195A9 (fr) 2003-10-23

Family

ID=27069137

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/012276 WO2001079195A2 (fr) 2000-04-14 2001-04-13 Nouveaux inhibiteurs de thrombine de type non covalent

Country Status (2)

Country Link
AU (1) AU2001255399A1 (fr)
WO (1) WO2001079195A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040106626A1 (en) * 2001-10-03 2004-06-03 Pharmacia Corporation 6-Membered unsaturated heterocyclic compounds useful for selective inhibition of the coagulation cascade
SI21097A (sl) 2001-12-04 2003-06-30 Univerza V Ljubljani Inhibitorji trombina
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
CA3159176A1 (fr) 2019-12-04 2021-06-10 Neil S. Cutshall Inhibiteurs de masp-2 et procedes d'utilisation
WO2021113698A1 (fr) 2019-12-04 2021-06-10 Omeros Corporation Inhibiteurs de masp-2 et procédés d'utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011158A (en) * 1994-12-13 2000-01-04 Corvas International, Inc. Aromatic heterocyclic derivatives as enzyme inhibitors
WO1997001338A1 (fr) * 1995-06-27 1997-01-16 Merck & Co., Inc. Inhibiteurs de la thrombine a base de pyridinone
JP2000512616A (ja) * 1996-02-22 2000-09-26 メルク エンド カンパニー インコーポレーテッド ピリジノントロンビンインヒビター
EP1017393A4 (fr) * 1997-09-05 2002-01-23 Merck & Co Inc Inhibiteurs de thrombine a base de pyrazinone
JP2002516326A (ja) * 1998-05-26 2002-06-04 メルク エンド カムパニー インコーポレーテッド イミダゾピリジン系トロンビン阻害薬
FR2786482B1 (fr) * 1998-11-27 2002-08-09 Synthelabo Nouveaux derives de 2-pyridone, leur preparation et leur application en therapeutique
PL352368A1 (en) * 1999-05-19 2003-08-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
PL352403A1 (en) * 1999-05-19 2003-08-25 Pharmacia Corp Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of coagulation cascade

Also Published As

Publication number Publication date
WO2001079195A2 (fr) 2001-10-25
WO2001079195A3 (fr) 2002-05-16
AU2001255399A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
AU693636B2 (en) Aromatic heterocyclic derivatives as enzyme inhibitors
US5656645A (en) Aromatic heterocyclic derivatives as enzyme inhibitors
US5658930A (en) Aromatic heterocyclic derivatives as enzyme inhibitors
US5637599A (en) Arginine mimic derivatives as enzyme inhibitors
US5932733A (en) 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
US5492895A (en) Inhibitors of thrombosis
US6034215A (en) 3-amino-2-oxo-1-piperidnercetic derivatives as enzyme inhibitors
WO1996018644A9 (fr) Derives aromatiques heterocycliques utilisables comme inhibiteurs d'enzymes
WO1997046207A2 (fr) Derives aromatiques heterocycliques utilises comme inhibiteurs enzymatiques
WO1995035311A9 (fr) Derives de l'acide 3-amino-2-oxo-1-piperidineacetique
WO1995035311A1 (fr) Derives de l'acide 3-amino-2-oxo-1-piperidineacetique
EP0765340A1 (fr) Derives du type methionine-sulfone et du type cysteine-sulfone substituee en s utilises comme inhibiteurs d'enzymes
US5714499A (en) 3-amino-2-oxo-1-piperidineacetic derivatives containing an arginine mimic as enzyme inhibitors
WO1999026920A1 (fr) Derives de 3-amino-2-hydroxyphenylacetamide substitue utilises en tant qu'inhibiteurs (ii) d'enzyme
WO2001079261A1 (fr) Derives de tetrahydro-azepinone servant d'inhibiteurs de la thrombine
US6506754B1 (en) Non-covalent thrombin inhibitors
US6541467B1 (en) Thrombin inhibitors having a lactam at P3
US5696231A (en) N-substituted glycine derivatives as enzyme inhibitors
WO2001079195A9 (fr) Nouveaux inhibiteurs de thrombine de type non covalent
US6777431B2 (en) Non-convalent thrombin inhibitors
US5955576A (en) Inhibitors of thrombosis
US6506760B1 (en) Substituted hydrazinyl heteroaromatic inhibitors of thrombin
US6342504B1 (en) Aromatic heterocyclic derivatives as enzyme inhibitors
US6506761B1 (en) Substituted hydrazinyl heteroaromatic inhibitors of thrombin
WO2001079193A2 (fr) Inhibiteurs heteroaromatiques hydrazinyl-substitues de la thrombine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
COP Corrected version of pamphlet

Free format text: PAGES 1/29-29/29, DRAWINGS, REPLACED BY NEW PAGES 1/25-25/25; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

NENP Non-entry into the national phase in:

Ref country code: JP